Stay updated on Pemigatinib Dose-Escalation Clinical Trial
Sign up to get notified when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.

Latest updates to the Pemigatinib Dose-Escalation Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedGastric cancer was added to the list of conditions for the study. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision: v3.4.1 replaces v3.4.0 on the page, a minor version update that does not affect study content or navigation. No substantive study information changes were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedAdded: Show glossary, 'Last Update Submitted that Met QC Criteria', No FEAR Act Data, and Revision: v3.4.0; Deleted: 'Last Update Submitted that met QC Criteria' (lowercase met), No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision: v3.3.4 added; previous v3.3.3 removed; no visible content or functionality changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check83 days agoChange DetectedLocations were added for AL, CA, CT, DC, FL, GA, MI, MO, NJ, NY, NC, OH, SC, and TX; the HHS Vulnerability Disclosure link was removed.SummaryDifference0.9%

Stay in the know with updates to Pemigatinib Dose-Escalation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.